Marathon Trading Investment Management LLC Lowers Holdings in Invivyd, Inc. (NASDAQ:IVVD)

Marathon Trading Investment Management LLC trimmed its holdings in Invivyd, Inc. (NASDAQ:IVVD) by 67.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 36,570 shares of the company’s stock after selling 75,330 shares during the quarter. Marathon Trading Investment Management LLC’s holdings in Invivyd were worth $40,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in shares of Invivyd by 3.9% in the first quarter. Vanguard Group Inc. now owns 2,611,202 shares of the company’s stock worth $11,594,000 after buying an additional 97,496 shares in the last quarter. Tidal Investments LLC bought a new position in shares of Invivyd during the 1st quarter valued at about $126,000. Acadian Asset Management LLC purchased a new position in shares of Invivyd during the first quarter valued at about $905,000. Jacobs Levy Equity Management Inc. increased its holdings in shares of Invivyd by 21.7% in the first quarter. Jacobs Levy Equity Management Inc. now owns 435,338 shares of the company’s stock worth $1,933,000 after purchasing an additional 77,603 shares during the last quarter. Finally, Cornercap Investment Counsel Inc. bought a new stake in shares of Invivyd in the second quarter worth about $86,000. 70.36% of the stock is owned by hedge funds and other institutional investors.

Invivyd Stock Up 5.4 %

Invivyd stock opened at $1.17 on Thursday. Invivyd, Inc. has a twelve month low of $0.81 and a twelve month high of $5.20. The company’s 50-day moving average price is $1.07 and its 200-day moving average price is $1.95. The company has a market cap of $139.60 million, a PE ratio of -0.63 and a beta of 0.61.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.03). The company had revenue of $2.26 million for the quarter, compared to the consensus estimate of $4.91 million. As a group, sell-side analysts expect that Invivyd, Inc. will post -0.6 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Invivyd in a report on Tuesday, September 3rd.

Invivyd Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.